Acute Porphyria Drug Database

C03AB01 - Bendroflumethiazide and Potassium
Propably not porphyrinogenic
PNP

Rationale
Sulfonamide type of drug. Clinical experience points to non-porphyrinogenicity. There are references that warn against the drug. Combined with potassium chloride.
Therapeutic characteristics
Thiazide diuretic and antihypertensive.
Metabolism and pharmacokinetics
The major part of the drug is eliminated via non-renal mechanisms, only 30 % excreted in unchanged form in urine. More specific data on metabolism are lacking. No observations of CYP interaction. Bendroflumethiazide is a sulfonamide type drug, a drug group often incriminated in acute porphyric attacks. Combined with potassium chloride.
Personal communication
Thunell, patient report (n=1): tolerated. Andersson, patient report (n=11): tolerated.
Published experience
None.
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.

References

  1. Scientific articles
  2. Beermann B, Groschinsky-Grind M, Lindstrom B. Pharmacokinetics of bendroflumethiazide. Clin Pharmacol Ther. 1977 Oct;22(4):385-8. PMID: 902450 PMID 902450. #4395

Similar drugs
Explore alternative drugs in similar therapeutic classes C03A / C03AB or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙